Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foliglurax PET Study in Healthy and PD Subjects
NCT04175132Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Nov 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of foliglurax in Parkinson's disease (PD) (2 arms), sponsored by Lundbeck. Primary endpoints: Receptor Occupancy (RO) on the metabotropic glutamate receptor 4 (mGlu4) at Day 3 and Concentration of foliglurax at PET scan time at Day 3. Started Nov 2019; status: terminated.
02
Drugs
foliglurax
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04175132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175132.